Vistec Lithography, a leading supplier of advanced electron-beam lithography systems has announced today that the International Iberian Nanotechnology Laboratory (INL) in Braga, Portugal has placed an order for Vistec's electron-beam lithography system EBPG5200.
Applied Materials, Inc. today announced that Shinsung Holdings Corp., a fast-growing manufacturer of high-efficiency solar photovoltaic cells and other high-technology products, has selected Applied's SmartFactory manufacturing automation solution to optimize productivity and drive down costs as they ramp production across all their solar manufacturing operations in Korea.
Mad City Labs Inc., the leading global manufacturer of flexure based nanopositioning systems capable of sub-nanometre positioning resolution has appointed Elliot Scientific as distributor of its products within the UK and Ireland.
Novelda AS, a fabless semiconductor company specializing in nanoscale wireless low-power technology for impulse radar, has been invited by the Norwegian government and Innovation Norway to exhibit at the prestigious EXPO 2010, taking place in Shanghai, China in September 2010.
Amtech Systems, Inc., a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and silicon wafers, today announced that its solar subsidiary, Tempress Systems, Inc., has received approximately $37 million in new solar orders for its diffusion processing systems from several new and existing customers in Asia.
Following the announcement in June this year of the collaboration between Beneq and ALD NanoSolutions, Beneq is proud to reveal that the first system for Particle ALD will be delivered to the Centre de Recherche Public - Gabriel Lippmann in Luxembourg.
enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, including inflammatory bowel disease (IBD) and diabetes, announced today that Dr. Russell J. Mumper has joined the Company's Scientific Advisory Board.
Proceeds will support completion of ongoing clinical trials and activities related to advancing the company's lead investigational product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection as a treatment for Acute Myeloid Leukemia (AML).